For patients with advanced-stage or poor-prognosis malignant lymphoma, high-dose
therapy with peripheral blood progenitor cell (PBPC) support may become a first-line …

The objective of this study was to identify factors associated with poor mobilization of
peripheral blood progenitor cells (PBPCs) or delayed platelet engraftment after high-dose …

High-dose chemotherapy with or without radiotherapy followed by autologous
transplantation of hematopoietic progenitor cells is an effective treatment for patients with …

Myeloablative treatment and peripheral blood progenitor cell (PBPC) transplantation are
increasingly used for lymphomas and leukemias. We have sought to optimize conditions for …

Peripheral blood progenitor cells (PBPC) were mobilized and harvested in 200 patients
treated for non‐Hodgkin's lymphoma (n= 148), Hodgkin's disease (n= 22) and multiple …

PURPOSE To define parameters that predict for rapid engraftment after peripheral-blood
stem-cell (PBSC) transplantation, progenitor thresholds, the proportion of patients who …

PURPOSE To evaluate the feasibility of a sequential high-dose therapy with peripheral-
blood progenitor-cell (PBPC) support in patients with follicular lymphoma. PATIENTS AND …

Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic
regimens in non-Hodgkin's lymphoma (NHL) patients. The study included 72 patients with …

A “hard to mobilize” patient was defined as one in whom≥ 1× 106CD 34, cells/kg cannot be
obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's …

Peripheral blood cell (PBC) rescue has become the mainstay for autologous transplantation
in patients with lymphoma, multiple myeloma, and solid tumors. Different methods of …